INCY Overview
Upcoming Projects (INCY)
-
Examining the Phase 3 POD1UM-303 Trial Results for Retifanlimab (Zynyz®) in Advanced Squamous Cell Carcinoma of the Anal Canal
Ticker: INCY
Execute By: Dec 31, 2025
Executed Projects (INCY)
-
Discussing Incyte's Phase 3 results for Povorcitinib in Patients With Hidradenitis Suppurativa.
Ticker: INCY
Executed On: Mar 28, 2025 at 02:30 PM EDT -
Discussing the upcoming phase 3 readout of povorcitinib in Hidradenitis Suppurativa, as well as other investigational agents including upadacitinib and sonelokimab
Tickers: INCY, ABBV, MLTX
Executed On: Jan 30, 2025 at 10:00 AM EST -
Discussing Incyte Corp's Phase 3 results of LBA-1 Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma, as discussed at the ASH Annual Meeting.
Ticker: INCY
Executed On: Dec 05, 2024 at 03:00 PM EST -
Examining the Phase 2 AGAVE-201 Trial Results for Axatilimab (Niktimvo) in Chronic Graft-Versus-Host Disease from Syndax (SNDX) and Incyte (INCY)
Tickers: SNDX, INCY
Executed On: Oct 21, 2024 at 03:30 PM EDT -
Examining the Phase 3 inMIND Study Results for Tafasitamab (Monjuvi) in Relapsed or Refractory Follicular Lymphoma from Incyte (INCY)
Ticker: INCY
Executed On: Sep 26, 2024 at 03:00 PM EDT -
A look at the P2 data presented at the American Academy of Dermatology Annual Meeting of Incyte's Opzelura in adult patients with hidradenitis suppurativa.
Ticker: INCY
Executed On: Mar 27, 2024 at 04:00 PM EDT -
Investigating the potential of two oral JAK inhibitors, Rinvoq (upadacitinib) from Abbvie and Povorcitinib (INCB54707) from Incyte Bio as treatments for non-segmental vitiligo.
Tickers: ABBV, INCY
Executed On: Nov 22, 2023 at 08:30 AM EST -
Discussing the Phase 1/2 study of the ALK2 inhibitor zilurgisertib as a monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis
Ticker: INCY
Executed On: Aug 22, 2023 at 12:30 PM EDT -
A Second Look: Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Ticker: INCY
Executed On: Apr 19, 2023 at 10:30 AM EDT -
A second view: Discussing the ASCO 2022 poster "A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis" from Karyopharm Therapeutics
Tickers: KPTI, INCY
Executed On: Apr 13, 2023 at 02:30 PM EDT -
Discussing the recent approval of Zynyz (Retifanlimab) from Incyte in merkel cell carcinoma (MCC).
Ticker: INCY
Executed On: Apr 05, 2023 at 09:00 AM EDT -
Discussing the ASCO 2022 poster "A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis" from Karyopharm Therapeutics
Tickers: KPTI, INCY
Executed On: Apr 03, 2023 at 12:00 PM EDT -
Getting a community dermatologist's perspective on plaque psoriasis non-steroid topical treatments including Roivant's VTAMA (tapinarof) and Arcutis' Zoryve (roflumilast)
Tickers: ROIV, ARQT, INCY
Executed On: Mar 07, 2023 at 01:00 PM EST -
Discussing Incyte’s Pemazyre (Pemigatinib) for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement, following FDA Approval
Ticker: INCY
Executed On: Nov 02, 2022 at 01:30 PM EDT -
A look at the recent approval of Eli Lilly and Incyte's Olumiant (baricitinib) and potential use in alopecia areata
Tickers: LLY, INCY
Executed On: Jun 17, 2022 at 02:45 PM EDT -
A Second View: Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: Apr 05, 2022 at 01:00 PM EDT -
Digging into Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker: INCY
Executed On: Apr 01, 2022 at 01:00 PM EDT -
Discussing the INCY's Opzelura Cream (Ruxolitinib) in treating atopic dermatitis with a prescriber
Ticker: INCY
Executed On: Mar 15, 2022 at 01:00 PM EDT
Expired Projects (INCY)
-
Discussing Incyte’s povorcitinib in treating hidradenitis suppurativa
Ticker: INCY
Execute By: Mar 31, 2023 -
Examining the Market Potential for JAKs treating moderate-to-severe alopecia areata
Tickers: CNCE, LLY, PFE, INCY
Execute By: Jun 23, 2022 -
Discussing Incyte Corporation's Opzelura Cream (Ruxolitinib) in Atopic dermatitis, following recent FDA Approval
Ticker: INCY
Execute By: Oct 31, 2021
Upcoming & Overdue Catalysts (INCY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (INCY)
-
Incyte (INCY) Posts Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease
Tickers: INCY, EQ
Occurred on: Jan 02, 2020 -
PDUFA date for Incyte's(INCY) Ruxolitinib in Graft versus host disease expected May 24, 2019
Ticker: INCY
Occurred on: May 24, 2019 -
Phase 1 poster presentation of Incyte's(INCY) INCMGA0012 in Solid tumors due at AACR April 1, 2019, 1pm.
Ticker: INCY
Occurred on: Apr 01, 2019 -
Incyte (INCY) phase 3 interim readout for Keytruda and epacadostat combo in advanced melanoma is expected in Q1, 2018. - Discontinued
Ticker: INCY
Occurred on: Apr 06, 2018 -
FDA Decision on Baricitinib Expected April 19 2017
Tickers: INCY, LLY
Occurred on: Apr 14, 2017 -
Incyte (INCY) Announces First Patient Treated in Pivotal Clinical Trial Program for Ruxolitinib (Jakafi) in Graft-versus-Host Disease
Ticker: INCY
Occurred on: Dec 30, 2016 -
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD)
Ticker: INCY
Occurred on: Jun 23, 2016 -
Incyte set to initiate Phase 3 study of epacadostat plus pembrolizumab in first-line advanced melanoma
Tickers: INCY, MRK
Occurred on: Jun 22, 2016 -
GITR and LSD1 programs to enter clinical trials in the first half of 2016.
Ticker: INCY
Occurred on: Jun 22, 2016 -
Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study
Ticker: INCY
Occurred on: Jun 22, 2016 -
New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera (PV)
Ticker: INCY
Occurred on: Jun 10, 2016 -
Incyte to Discontinue Phase 3 study (JANUS 1) of Ruxolitinib Plus Capecitabine
Ticker: INCY
Occurred on: Feb 11, 2016 -
Phase 3 data of Ruxolitinib - JANUS 1 trial for pancreatic, colorectal and breast cancer due 2016
Ticker: INCY
Occurred on: Feb 11, 2016 -
NDA filing of Baricitinib for Rheumatoid arthritis to be filed by partner Eli Lilly in 2016
Ticker: INCY
Occurred on: Jan 19, 2016
Strategic Initiatives (INCY)
-
Incyte (INCY) and Agenus (AGEN) Announce Amended Collaboration Agreement
Tickers: AGEN, INCY
Announcement Date: Feb 14, 2017 -
Incyte (INCY) and Merck (MRK) Expand Collaboration Agreement Investigating Epacadostat + Keytruda in Solid Tumors and Blood Cancers
Tickers: MRK, INCY
Announcement Date: Jan 09, 2017 -
Incyte (INCY) and Merus N.V (MRUS) Reach Collaboration Agreement to Discover and Develop Bispecific Antibodies
Tickers: INCY, MRUS
Announcement Date: Dec 21, 2016 -
Incyte acquires the European operation of ARIAD Pharmaceuticals for $140M upfront plus milestones and tiered royalties
Tickers: INCY, ARIA
Announcement Date: May 09, 2016 -
AstraZeneca and Incyte announce new lung cancer clinical trial collaboration
Tickers: AZN, INCY
Announcement Date: Jan 11, 2016
